A phase 3 trial comparing first-line ivonescimab monotherapy to pembrolizumab monotherapy in patients with metastatic NSCLC whose tumors have high PD-L1 expression.

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 04 Nov 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

30 Oct 2024 According to Summit Therapeutics media release, The sample size for this study is currently planned to be an estimated 780 patients with two primary endpoints, PFS and OS.
10 Sep 2024 New trial record
08 Sep 2024 According to Summit Therapeutics media release, this trial is expected to begin in early 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com